equecabtagene autoleucel

AXP000021.1 · CAR-T cell therapy

Platform
autologous CAR-T
Targets
TNFRSF17
Originator
IASO Biotherapeutics
Sponsor
IASO Biotherapeutics

Names

NameTypeSource
equecabtagene autoleucelpreferred name, INNcurator, ncit
Fucasobrandpress
CT103Acodencit
IBI326codepress
eque-celsynonympress

Virus

Role
Ex vivo gene transfer
Family
Retroviridae
Virus
lentivirus
Replication
non replicating
Modifications
lentiviral vector carrying a CAR with a fully human scFv against BCMA, a CD8 alpha hinge and transmembrane region, a 4-1BB costimulatory domain and a CD3 zeta activation domain
Transgenes
anti-BCMA chimeric antigen receptor
Route
ex vivo, intravenous
Carrier
autologous T cells
Source
evidence

Cross-references

NCI Thesaurus
C185123
FDA UNII
YTJ3XRJ4ZN

Approvals

AgencyRegionDateStatusBrandIndicationSource
NMPACN2023-07approvedFucasoAdults with relapsed or refractory multiple myeloma after three or more prior lines including at least one proteasome inhibitor and an immunomodulatory agentsource

Clinical trials (12)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07752264A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing MyopathyNot yet recruitingPhase 1/22026-08-152030-08-1527Refractory Immune-mediated Necrotizing Myopathy
NCT07510100Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingPhase 1/22026-05-102029-08-3117Relapsed/Refractory Multiple Myeloma
NCT07055724Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL AmyloidosisNot yet recruitingPhase 22025-072027-0617AL Amyloidosis
NCT06902844Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)Recruiting2025-04-052027-10-316Lupus Nephritis (LN); Systemic Lupus Erythematosus (SLE)
NCT07028970Long-term Follow-up Registry Study of Equecabtagene Autoleucel InjectionRecruiting2024-12-152040-121500Multiple Myeloma
NCT06369935A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.Not yet recruiting2024-06-202026-08-20260Relapsed/Refractory Multiple Myeloma
NCT06464991A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active not recruitingPhase 32024-03-272027-08260Multiple Myeloma
NCT05698303A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple MyelomaUnknownPhase 12023-05-082024-05-2012Multiple Myeloma
NCT05181501A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)Not yet recruitingPhase 12022-042024-0420Multiple Myeloma
NCT05201118A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple MyelomaUnknownPhase 12022-01-012022-12-3120Extramedullary Multiple Myeloma
NCT04561557Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous SystemRecruitingEarly phase 12020-09-222027-02-2236Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Autoimmune Encephalitis; Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Idiopathic Inflammatory Myopathies; Multiple Sclerosis; Myasthenia Gravis; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD); Neuromyelitis Optica Spectrum Disorder; POEMS Syndrome
NCT05066646A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)UnknownPhase 1/22020-04-012022-10132Multiple Myeloma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42775240Relapsed/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B-cell maturation antigen-directed chimeric antigen receptor T-cell immunotherapy in an advanced disease stage: A case report.Experimental and therapeutic medicine2026name in abstract: equecabtagene autoleucel
PMID 42845783Equecabtagene autoleucel as sequential therapy in a multiple myeloma patient with renal failure: a case report.Frontiers in medicine2026name in title: equecabtagene autoleucel
PMID 42867544BCMA CAR T-cell therapy in a patient with heavily pretreated relapsed/refractory POEMS Syndrome: a case report.Annals of hematology2026name in abstract: equecabtagene autoleucel
PMID 40308587First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comorbidities: a case report.Frontiers in immunology2025name in abstract: equecabtagene autoleucel
PMID 40380297Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma.Journal of translational medicine2025name in abstract: equecabtagene autoleucel
PMID 40425008Anti-BCMA CAR-T cell therapy in relapsed/refractory chronic inflammatory demyelinating polyneuropathy.Med (New York, N.Y.)2025cited by trial NCT04561557
PMID 41101309Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis.Cell2025cited by trial NCT04561557
PMID 36596762Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.Signal transduction and targeted therapy2023name in title: CT103A
PMID 37192741Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.British journal of haematology2023cited by trial NCT05066646
PMID 37658205Equecabtagene Autoleucel: First Approval.Molecular diagnosis & therapy2023cited by trial NCT04561557
PMID 36137648Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.Journal for immunotherapy of cancer2022name in abstract: CT103A
PMID 33512480A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.Blood2021name in title: CT103A

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 414286222025 Update of Cellular Immunotherapy for Plasma Cell Disorders.Turkish journal of haematology : official journal of Turkish Society of Haematology2026name in abstract: eque-cel
PMID 41721717Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma.Hematological oncology2026name in abstract: equecabtagene autoleucel
PMID 39520053Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myeloma.Molecular therapy : the journal of the American Society of Gene Therapy2025name in title: CT103A
PMID 41176941CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell-driven neuroinflammation.Multiple sclerosis and related disorders2025name in abstract: CT103A
PMID 41439964Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma.Cells2025name in abstract: CT103A
PMID 38821074Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.The Lancet. Oncology2024name in abstract: equecabtagene autoleucel
PMID 39509090Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial.JAMA oncology2024name in title: equecabtagene autoleucel
PMID 37964302A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma.Journal of translational medicine2023name in abstract: CT103A
PMID 35185564A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy.Frontiers in pharmacology2022name in title: CT103A
PMID 35402835CT103A, a forward step in multiple myeloma immunotherapies.Blood science (Baltimore, Md.)2021name in title: CT103A

Notes

Fully human anti-BCMA scFv CAR; co-developed by IASO Bio and Innovent (IBI326). Approved in China 2023.

How to cite

equecabtagene autoleucel (AXP000021.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000021.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.